Ampio Pharmaceuticals Inc.

Robbins LLP Is Investigating the Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) breached their fiduciary duties to shareholders. Ampio develops therapies for the treatment of prevalent inflammatory conditions in the United States.

Ampio Announces Delay in Ampion Results Due to Flaw in Phase III Testing

On August 21, 2014, the share price of Ampio’s stock dropped 24% after the company announced that the recent phase III study of the drug Ampion may have been flawed and final results would be delayed. In a letter to shareholders on August 25, 2014, the company explained that during the study there was a point where the chemical being tested allegedly froze, which is believed to have affected the level of active ingredients in the dosage of Ampion.

Ampio Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.